

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: **ISPH-0852USA**

Customer No.: **55389**

Applicants: **C. Frank Bennett,  
Thomas P. Condon**

Confirmation No.: **5614**

Serial No.: **10/559,401**

Group Art Unit: **not assigned**

Filed: **12/05/2005**

Examiner: **not assigned**

Title: **OLIGONUCLEOTIDE MODULATION OF CELL ADHESION**

Mail Stop Missing Parts  
Commissioner For Patents  
P.O.Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37  
C.F.R. §§ 1.821 THROUGH 1.825


Dear Sir:

I hereby state that the amendments, made in accordance with 37 C.F.R. § 1.825(a), included in the substitute Sequence Listing are supported throughout the application, as filed. I hereby state that the substitute Sequence Listing does (do) not include new matter.

I hereby state that the copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the amended Sequence Listing.

Respectfully submitted,

Date: 9/11/08

  
Teresa Y. Liang, Ph.D.  
Registration No. 51,946

Isis Pharmaceuticals  
1896 Rutherford Road  
Carlsbad, CA 92008  
Telephone: (760) 603-4601